Prevention of Clostridium difficile-associated disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,156.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI078566-01
Award Id:
88752
Agency Tracking Number:
AI078566
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
MIDI, INC., 125 SANDY DR, NEWARK, DE, 19713
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
804737278
Principal Investigator:
() -
Business Contact:
() -
myron@midi-inc.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Clostridium difficile-associated disease (CDAD) is a hospital-acquired problem following routine antibiotic treatment. Its impact may exceed that of any other nosocomial infection. Spores of the toxin-producing pathogen are highly resistant to antibiotics and therefore overgrow the gut when broad-spectrum oral antibiotics kill off the competing bacteria. The C. difficile spores are resistant to common hospital disinfectants, thus contaminating the hospital environment an d providing inoculum for infection of patients, especially the highly vulnerable elderly. Disease symptoms include diarrhea and pseudomembranous colitis. Treatment of the disease is with metronidazole or vancomycin, but relapse is commonly more than 20%. R ecent spread of a more aggressive strain, that produces toxins A and B at 16 times and 23 times greater, a binary toxins, is resistant to fluoroquinolones, is hyper-productive of spores, and leads to mortality rates greater than 16%. The proposed research is to develop adjuvants for routinely used antibiotics, enabling reduction of numbers of spores in the gut and subsequently inhibiting the germination and growth of C. difficile. The treatment should prevent C. difficile overgrowth of the GI tract, allowin g competing bacteria to colonize the gut and suppress the growth of C. difficile and CDAD. PUBLIC HEALTH RELEVANCE: Clostridium difficile-associated disease (CDAD) is caused by antibiotic treatment and has become the most costly and injurious hospital-acqu ired infection. This SBIR research proposes prevention of CDAD through the use of adjuvants with the antibiotics.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government